PURPOSE: To evaluate the therapeutic effect of intravitreal bevacizumab in patients with uveitis-associated choroidal/retinal neovascularization. METHODS: Two female patients (40 years, 15 years) with posterior uveitis, (one presumed ocular sarcoidosis, one lupus) were evaluated for neovascularization of the posterior segment. Both patients were given a single dose of 1.25 mg intravitreal bevacizumab. RESULTS: Significant anatomical and functional recovery was evident in both patients within a few weeks. CONCLUSION: In selected uveitic patients, bevacizumab may be an option for managing neovascularization.
PURPOSE: To evaluate the therapeutic effect of intravitreal bevacizumab in patients with uveitis-associated choroidal/retinal neovascularization. METHODS: Two female patients (40 years, 15 years) with posterior uveitis, (one presumed ocular sarcoidosis, one lupus) were evaluated for neovascularization of the posterior segment. Both patients were given a single dose of 1.25 mg intravitreal bevacizumab. RESULTS: Significant anatomical and functional recovery was evident in both patients within a few weeks. CONCLUSION: In selected uveitic patients, bevacizumab may be an option for managing neovascularization.
Authors: Apurva K Patel; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; H Nida Sen; Pichaporn Artornsombudh; Srishti Kothari; John H Kempen Journal: Ophthalmology Date: 2015-12-11 Impact factor: 12.079